Voriconazole
FDA-approved product (tablet, oral), marketed as Vfend, Voriconazole.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Aspergillosis
- Bacterial Infections and Mycoses
- Candidemia
- Candidiasis
- Fungal infectious disease
- Fusariosis
- Infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Triazole and tetrazole derivatives
- FDA pharmacologic class
- Azole Antifungal FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC03; FDA class Azole Antifungal
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Voriconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
NCT00066599 · start 2003-06
Registered record
- Registry ID
- NCT00066599
- Conditions
- Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Neutropenia; Sarcoma
- Interventions
- voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2004-06
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm +5 moreInterventionvoriconazolePhasePhase 2Registry statusCompletedA Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children
NCT00174473 · start 2003-06
Registered record
- Registry ID
- NCT00174473
- Conditions
- Neutropenia
- Interventions
- Voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2003-06
- Completion
- 2005-08
- Enrolment
- 49
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeutropeniaInterventionVoriconazolePhasePhase 1 / Phase 2Registry statusCompletedVoriconazole to Prevent Systemic Fungal Infections in Children
NCT00005912 · start 2000-06
Registered record
- Registry ID
- NCT00005912
- Conditions
- Aspergillosis; Candidiasis; Fungal Diseases; Mycoses
- Interventions
- Voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2000-06
- Completion
- 2001-01
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAspergillosis; Candidiasis; Fungal Diseases; MycosesInterventionVoriconazolePhasePhase 1Registry statusCompletedVoriconazole to Treat Fungal Infections
NCT00001940 · start 1999-12
Registered record
- Registry ID
- NCT00001940
- Conditions
- Mycoses
- Interventions
- Voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-12
- Completion
- 2001-07
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMycosesInterventionVoriconazolePhasePhase 3Registry statusCompletedAn Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
NCT00001757 · start 1997-11
Registered record
- Registry ID
- NCT00001757
- Conditions
- Mycoses
- Interventions
- Voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1997-11
- Completion
- 2000-07
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMycosesInterventionVoriconazolePhasePhase 3Registry statusCompleted